7-溴噻吩并[3,2-d]嘧啶 | 21586-25-4

• 物质功能分类: 医药中间体 - 杂环化合物 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并嘧啶酮衍生物
• 中文名称: 7-溴噻吩并[3,2-d]嘧啶
• 中文别名: 7-溴噻吩并[3,2-D]嘧啶
• 英文名称: 7-bromothieno[3,2-d]pyrimidine
• 英文别名: 7-Brom-thieno<3,2-d>pyrimidin
• CAS: 21586-25-4
• 化学式: C₆H₃BrN₂S
• 分子量: 215.073
• InChiKey: PDQOYFDDMSKPQP-UHFFFAOYSA-N

物化性质

• 熔点：
  173 °C
• 沸点：
  309.8±22.0 °C(Predicted)
• 密度：
  1.859±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  T
• 安全说明：
  S45
• 危险类别码：
  R25
• 海关编码：
  2934999090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H317,H319

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 7-Bromothieno[3,2-D]Pyrimidine
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 3), H301
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
T Toxic R25
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Danger
Hazard statement(s)
H301 Toxic if swallowed.
Precautionary statement(s)
P301 + P310 IF SWALLOWED: Immediately call a POISON CENTER or doctor/
physician.
Supplemental Hazard none
Statements
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

---

SECTION 3: Composition/information on ingredients
Substances
Molecular weight : 215,07 g/mol
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
7-Bromothieno[3,2-D]Pyrimidine
Acute Tox. 3; H301 <= 100 %
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
7-Bromothieno[3,2-D]Pyrimidine
T, R25 <= 100 %
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Take victim immediately to hospital. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
No data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Nature of decomposition products not known.
Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.
Further information
No data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Wear respiratory protection. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Storage class (TRGS 510): Non-combustible, acute toxic Cat.3 / toxic hazardous materials or hazardous
materials causing chronic effects
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling
the product.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under
appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face particle
respirator type N99 (US) or type P2 (EN 143) respirator cartridges as a backup to engineering
controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use
respirators and components tested and approved under appropriate government standards such
as NIOSH (US) or CEN (EU).
Control of environmental exposure
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour No data available
c) Odour Threshold No data available
d) pH No data available
e) Melting point/freezing No data available
point
f) Initial boiling point and No data available
boiling range
g) Flash point No data available
h) Evaporation rate No data available
i) Flammability (solid, gas) No data available
j) Upper/lower No data available
flammability or
explosive limits
k) Vapour pressure No data available
l) Vapour density No data available
m) Relative density No data available
n) Water solubility No data available
o) Partition coefficient: n- No data available
octanol/water
p) Auto-ignition No data available
temperature
q) Decomposition No data available
temperature
r) Viscosity No data available
s) Explosive properties No data available
t) Oxidizing properties No data available
Other safety information
No data available

---

SECTION 10: Stability and reactivity
Reactivity
No data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
No data available
Conditions to avoid
No data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
No data available
Persistence and degradability
No data available
Bioaccumulative potential
No data available
Mobility in soil
No data available
Results of PBT and vPvB assessment
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
Other adverse effects
No data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: 2811 IMDG: 2811 IATA: 2811
UN proper shipping name
ADR/RID: TOXIC SOLID, ORGANIC, N.O.S. (7-Bromothieno[3,2-D]Pyrimidine)
IMDG: TOXIC SOLID, ORGANIC, N.O.S. (7-Bromothieno[3,2-D]Pyrimidine)
IATA: Toxic solid, organic, n.o.s. (7-Bromothieno[3,2-D]Pyrimidine)
Transport hazard class(es)
ADR/RID: 6.1 IMDG: 6.1 IATA: 6.1
Packaging group
ADR/RID: III IMDG: III IATA: III
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
No data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
No data available
Chemical Safety Assessment
For this product a chemical safety assessment was not carried out

---

SECTION 16: Other information
Full text of H-Statements referred to under sections 2 and 3.
Acute Tox. Acute toxicity
H301 Toxic if swallowed.
Full text of R-phrases referred to under sections 2 and 3
T Toxic
R25 Toxic if swallowed.
Further information
Copyright 2014 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

反应信息

• 作为反应物：
  描述：

  7-溴噻吩并[3,2-d]嘧啶 在 potassium carbonate 、 三氯氧磷 作用下， 以 乙腈 为溶剂， 反应 5.0h， 生成
  参考文献：
  名称：

  通过连续 SNAr 和 Suzuki 反应合成噻吩并[3,2-d]嘧啶衍生物作为选择性 h-NTPDase 抑制剂

  摘要：

  噻吩并嘧啶支架已显示出对四种外核苷三磷酸二磷酸水解酶（NTPDase）同工型的选择性抑制作用。通过SN Ar 和Suzuki 偶联完成了对核心噻吩并嘧啶的修饰。这些修饰对应于h- NTPDase1、h- NTPDase2、h- NTPDase3 和h- NTPDase8 的选择性抑制。分子对接研究支持了针对酶的体外结果。

  DOI：

  10.1002/cmdc.202300165
• 作为产物：
  描述：

  4-氯噻吩并[3,2-d]嘧啶 在 吡啶 、 溴 、 氧气 、 sodium ethanolate 、 一水合肼 作用下， 以 四氯化碳 、 乙醇 为溶剂， 反应 2.0h， 生成 7-溴噻吩并[3,2-d]嘧啶
  参考文献：
  名称：

  噻吩并嘧啶类-Ⅱ：噻吩并[3.2- d ]嘧啶等

  摘要：

  已经研究了4-氯噻吩并[3.2- d ]嘧啶的亲核取代。噻吩并[3.2-的合成d ]嘧啶通过催化还原4-氯噻吩并[3,2所作d ]嘧啶和由4-肼噻吩并[3,2的氧化d ]嘧啶。噻吩并[3.2- d ]嘧啶的亲电取代产生在C-7处带有取代基的衍生物。给出了各种噻吩并[3.2- d ]嘧啶的NMR光谱数据，分配给新化合物的结构与光谱数据一致。

  DOI：

  10.1016/s0040-4020(01)90718-5

文献信息

• 7-AMINOFUROPYRIDINE DERIVATIVES
  申请人：Hornberger Keith R.

  公开号：US20120046267A1

  公开（公告）日：2012-02-23

  Compounds of Formula 1, as shown below and defined herein: pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by TAK1 or for which an appropriate TAK1 inhibitor is effective. This Abstract is not limiting of the invention.

  公式1的化合物，如下所示并在此定义：其药学上可接受的盐，合成方法，中间体，配方以及使用它们进行疾病治疗的方法，包括治疗癌症，例如由TAK1至少部分驱动的肿瘤或适当的TAK1抑制剂有效的肿瘤。本摘要不限于该发明。
• 7-aminofuropyridine derivatives
  申请人：Hornberger Keith R.

  公开号：US08378104B2

  公开（公告）日：2013-02-19

  Compounds of Formula 1, as shown below and defined herein: pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by TAK1 or for which an appropriate TAK1 inhibitor is effective. This Abstract is not limiting of the invention.

  本发明涉及公式1的化合物，如下所示并在此定义：其药学上可接受的盐，合成方法，中间体，制剂以及使用其进行疾病治疗的方法，包括治疗癌症，例如由TAK1驱动或适用于TAK1抑制剂有效的肿瘤。本摘要不限制本发明。
• [EN] CDK INHIBITORS AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE CDK ET LEURS PROCÉDÉS D'UTILISATION
  申请人：RELAY THERAPEUTICS INC

  公开号：WO2022174031A1

  公开（公告）日：2022-08-18

  The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of CDK enzymes with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with CDK signaling with the compounds and compositions of the disclosure.

  本文涉及新型化合物及其制药组合物，以及使用本文所述的化合物和组合物抑制CDK酶活性的方法。本文还涉及但不限于使用本文所述的化合物和组合物治疗与CDK信号相关的疾病的方法。
• Enabling synthesis in fragment-based drug discovery (FBDD): microscale high-throughput optimisation of the medicinal chemist's toolbox reactions
  作者：Chloe Townley、Davide Branduardi、Gianni Chessari、Benjamin D. Cons、Charlotte Griffiths-Jones、Richard J. Hall、Christopher N. Johnson、Yuji Ochi、Stuart Whibley、Rachel Grainger

  DOI：10.1039/d3md00495c

  日期：——

  modern automated synthesis technique largely differs to the way organic chemists are traditionally trained. To make HTE accessible to all our synthetic chemists we have developed a semi-automated workflow enabled by pre-made 96-well screening kits, rapid analytical methods and in-house software development, which is empowering chemists at Astex to run HTE screens independently with minimal training.

  小型化高通量实验 （HTE） 广泛用于工业和学术实验室，用于使用材料受限的多因素反应条件筛选来快速优化反应。在基于片段的药物发现 （FBDD） 中，常见的工具箱反应（如 Suzuki-Miyaura 和 Buchwald-Hartwig 交叉偶联）可能会受到片段内在富含杂原子的药效团的阻碍，而配体-蛋白质结合需要这种药效团。在 Astex，我们正在使用微量 HTE 来加速反应优化并防止降低靶标优先级。通过确定可耐受未保护杂原子的催化剂/碱/溶剂组合，我们可以快速优化关键交叉偶联，并通过避免多余的保护基团操作来加快路线设计。然而，HTE 需要大量的前期培训，而且这种现代自动化合成技术与传统有机化学家的培训方式大不相同。为了让所有合成化学家都能使用 HTE，我们开发了一种半自动化工作流程，由预制的 96 孔筛选试剂盒、快速分析方法和内部软件开发提供支持，使 Astex 的化学家能够独立运行 HTE
• Robba,M. et al., Comptes Rendus des Seances de l'Academie des Sciences, Serie C: Sciences Chimiques, 1968, vol. 267, p. 697 - 700
  作者：Robba,M. et al.

  DOI：——

  日期：——